RET and non-small cell lung carcinoma: Another multicenter retrospective analysis revealed that RET-positive NSCLC patients treated with single-agent immunotherapy had a median progression-free survival (PFS) of only 2.1 months, suggesting that RET gene NSCLC patients may not benefit from adjuvant immunotherapy [9].